Will West

CellCentric

Will is CEO of CellCentric and an investor advisor to Morningside. He gained a PhD in Immunology and Virology, sponsored by UniPath (Unilever), before holding a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC). He went on to Procter & Gamble Healthcare, where he was responsible for clinical development in a number of therapeutic areas, including respiratory and GI. He led and delivered Phase I-III clinical programmes throughout Europe, the Americas, South Africa and China. Will co-founded and leads CellCentric, a clinical stage biotech company developing a first in class oral drug for the treatment of multiple myeloma. The programme is entering registration studies late 2025. Will advises and represents other Morningside biotech interests, including Cyted (cancer diagnostics) and F2G (anti-fungal therapy). He was Executive Chair of VaxEquity (saRNA for vaccines and therapeutics) during and after the Covid pandemic. Previously he was appointed by the Science Minister to the Council of the BBSRC, the UK’s leading funder of bioscience research. He subsequently took over as Chair of the John Innes Centre, the world-leading research institute focused on plant science and microbiology. Will was formerly elected to the Board of the BioIndustry Association, and subsequently was part of the Executive Committee. In addition to his doctorate, Will holds a Masters degree in Clinical Research as well as an MBA from London Business School.